Hyperamylasemia in ovarian tumours - serum amylase as a marker for ovarian cancers (?)

Benedicta D'Souza, Sreekantha, Vivian D'Souza

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Ovarian cancer is uncontrolled growth of abnormal ovarian cells. Ovarian cancer is the most common cause of cancer death among women, since no signs and symptoms are manifested at the early stage of the disease and the disease is diagnosed only in advanced stage. There is a strong need for a tumour marker for early diagnosis and to monitor the response of ovarian cancer patients to therapy Objective: To estimate serum amylase levels in benign, malignant ovarian tumour and ovarian cyst. Materials and Methods: Twenty five women with diagnosed ovarian cancer, twenty five benign ovarian tumor and twenty five ovarian cyst patients and 25 normal healthy women were selected for the study. Serum amylase activity is estimated by commercially available kit called CNPG 3 reagent set. Result: The serum amylase levels were significantly elevated (p< 0.001) in patients suffering from malignant ovarian tumours when compared to control. Conclusion: We conclude that estimation of serum amylase can be used as marker in the diagnosis and follow up cases of ovarian cancer patients.

Original languageEnglish
Pages (from-to)445-449
Number of pages5
JournalInternational Journal of Pharma and Bio Sciences
Volume2
Issue number1
Publication statusPublished - 01-12-2011
Externally publishedYes

Fingerprint

Hyperamylasemia
Amylases
Ovarian Neoplasms
Tumors
Serum
Ovarian Cysts
Neoplasms
Tumor Biomarkers
Signs and Symptoms
Early Diagnosis
Cause of Death
Growth

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

D'Souza, Benedicta ; Sreekantha ; D'Souza, Vivian. / Hyperamylasemia in ovarian tumours - serum amylase as a marker for ovarian cancers (?). In: International Journal of Pharma and Bio Sciences. 2011 ; Vol. 2, No. 1. pp. 445-449.
@article{5ec12143dfab4b798243861bd54c230d,
title = "Hyperamylasemia in ovarian tumours - serum amylase as a marker for ovarian cancers (?)",
abstract = "Background: Ovarian cancer is uncontrolled growth of abnormal ovarian cells. Ovarian cancer is the most common cause of cancer death among women, since no signs and symptoms are manifested at the early stage of the disease and the disease is diagnosed only in advanced stage. There is a strong need for a tumour marker for early diagnosis and to monitor the response of ovarian cancer patients to therapy Objective: To estimate serum amylase levels in benign, malignant ovarian tumour and ovarian cyst. Materials and Methods: Twenty five women with diagnosed ovarian cancer, twenty five benign ovarian tumor and twenty five ovarian cyst patients and 25 normal healthy women were selected for the study. Serum amylase activity is estimated by commercially available kit called CNPG 3 reagent set. Result: The serum amylase levels were significantly elevated (p< 0.001) in patients suffering from malignant ovarian tumours when compared to control. Conclusion: We conclude that estimation of serum amylase can be used as marker in the diagnosis and follow up cases of ovarian cancer patients.",
author = "Benedicta D'Souza and Sreekantha and Vivian D'Souza",
year = "2011",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "445--449",
journal = "International Journal of Pharma and Bio Sciences",
issn = "0975-6299",
publisher = "International Journal of Pharma and Bio Sciences",
number = "1",

}

Hyperamylasemia in ovarian tumours - serum amylase as a marker for ovarian cancers (?). / D'Souza, Benedicta; Sreekantha; D'Souza, Vivian.

In: International Journal of Pharma and Bio Sciences, Vol. 2, No. 1, 01.12.2011, p. 445-449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hyperamylasemia in ovarian tumours - serum amylase as a marker for ovarian cancers (?)

AU - D'Souza, Benedicta

AU - Sreekantha,

AU - D'Souza, Vivian

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: Ovarian cancer is uncontrolled growth of abnormal ovarian cells. Ovarian cancer is the most common cause of cancer death among women, since no signs and symptoms are manifested at the early stage of the disease and the disease is diagnosed only in advanced stage. There is a strong need for a tumour marker for early diagnosis and to monitor the response of ovarian cancer patients to therapy Objective: To estimate serum amylase levels in benign, malignant ovarian tumour and ovarian cyst. Materials and Methods: Twenty five women with diagnosed ovarian cancer, twenty five benign ovarian tumor and twenty five ovarian cyst patients and 25 normal healthy women were selected for the study. Serum amylase activity is estimated by commercially available kit called CNPG 3 reagent set. Result: The serum amylase levels were significantly elevated (p< 0.001) in patients suffering from malignant ovarian tumours when compared to control. Conclusion: We conclude that estimation of serum amylase can be used as marker in the diagnosis and follow up cases of ovarian cancer patients.

AB - Background: Ovarian cancer is uncontrolled growth of abnormal ovarian cells. Ovarian cancer is the most common cause of cancer death among women, since no signs and symptoms are manifested at the early stage of the disease and the disease is diagnosed only in advanced stage. There is a strong need for a tumour marker for early diagnosis and to monitor the response of ovarian cancer patients to therapy Objective: To estimate serum amylase levels in benign, malignant ovarian tumour and ovarian cyst. Materials and Methods: Twenty five women with diagnosed ovarian cancer, twenty five benign ovarian tumor and twenty five ovarian cyst patients and 25 normal healthy women were selected for the study. Serum amylase activity is estimated by commercially available kit called CNPG 3 reagent set. Result: The serum amylase levels were significantly elevated (p< 0.001) in patients suffering from malignant ovarian tumours when compared to control. Conclusion: We conclude that estimation of serum amylase can be used as marker in the diagnosis and follow up cases of ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=79961061167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961061167&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 445

EP - 449

JO - International Journal of Pharma and Bio Sciences

JF - International Journal of Pharma and Bio Sciences

SN - 0975-6299

IS - 1

ER -